Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
NCT ID: NCT01170338
Last Updated: 2010-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Varenicline on Brain Activity During Nicotine Abstinence
NCT00602927
Varenicline for Smoking Cessation in Heavy Drinking Smokers
NCT00860028
Varenicline for the Treatment of Smokeless Tobacco
NCT00813917
Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation
NCT02575183
Varenicline (Chantix™) for the Treatment of Alcohol Dependence
NCT00705523
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
active Chantix
active drug to help smoking cessation
Varenicline 100 mg by mouth twice daily
this is an active drug to help smoking cessation
sugar pill
control
this is the placebo that will help us maintain a blinded study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Varenicline 100 mg by mouth twice daily
this is an active drug to help smoking cessation
control
this is the placebo that will help us maintain a blinded study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Newark Beth Israel Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Newark Beth Israel Medical Ctr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Newark Beth Israel Medical Center
Newark, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008.68
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.